Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review. (PubMed, Front Endocrinol (Lausanne)) - Sep 25, 2026 - "Selective RET inhibitors, particularly selpercatinib, have recently emerged as a promising treatment option, with all five reported cases demonstrating rapid biochemical improvement and radiologic responses...Two cases received vandetanib producing favorable biochemical (calcitonin) and radiologic responses...Emerging data suggests that selective RET inhibitors may lead to simultaneous control of both tumor progression and cortisol excess in RET-mutated disease, although current data remain limited to case reports. The four institutional cases offer additional real-world clinical context and are presented separately from the systematic review to maintain methodological rigor."
Journal • Review • Cushing's Disease • Endocrine Disorders • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET
|
|
Andrei Muresan; Corin Badiu; Dumitru Ioachim; Laura-Semonia Stanescu; Monica Livia Gheorghiu; Romeo Smarandache; Sofia-Maria Lider-Burciulescu
|